Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

DAFTAR PUSTAKA

Ahmed, M., 2012. Isoniazid-Associated Uric Acid Retention in the Lizard, Uromastix hardwickii 3.

Aibana, O., Bachmaha, M., Krasiuk, V., Rybak, N., Flanigan, T.P., Petrenko, V., dkk., 2017. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. *BMC infectious diseases*, **17**: 129.

Akshata, J.S., Swapna, R., Chakraborty, A., Somashekar, M., dan Buggi, S., 2015. Hypothyroidism in MDR-TB treatment – Rare occurrence but a major concern. *Egyptian Journal of Chest Diseases and Tuberculosis*, **64**: 671–674.

Aminy, R.Z. dan Mardiana, N., 2020. Bartter-like Syndrome In a Patient Receiving Capreomycin For The Treatment Of Multidrug-Resistant Tuberculosis. *Current Internal Medicine Research and Practice Surabaya Journal*, **1**: 44.

Anderson, L.F., Tamne, S., Watson, J.P., Cohen, T., Mitnick, C., Brown, T., dkk., 2013. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. *Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin*, **18**: 20601.

Ardhianto, D., Suharjono, Soedarsono, dan Fatmawati, U., 2021. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 421–427.

Arroyo, L.Á., Gil, M.P., Grana, E.C., dan Baines, J.P.O., 2007. Trombocitopenia grave inducida por levofloxacino. *Farmacia Hospitalaria*, **31**: 2.

Auclair, B., Nix, D.E., Adam, R.D., James, G.T., dan Peloquin, C.A., 2001. Pharmacokinetics of Ethionamide Administered under Fasting Conditions or with Orange Juice, Food, or Antacids. *Antimicrobial Agents and Chemotherapy*, **45**: 810–814.

Azhar, W., Zaidi, F., dan Hannan, A., 2020. Isoniazid Induced Pure Red Blood Cell Aplasia. *Cureus*, .

Badrinath, M. dan John, S., 2022. Isoniazid Toxicity, dalam: *StatPearls*. StatPearls Publishing, Treasure Island (FL).

Bailey, S.L. dan Grant, P., 2011. 'The tubercular diabetic': the impact of diabetes mellitus on tuberculosis and its threat to global tuberculosis control. *Clinical Medicine*, **11**: 344–347.

Banerjee, S. dan Banerjee, M., 2005. Diabetes and tuberculosis interface. *Journal of the Indian Medical Association*, **103**: 318, 320, 322 passim.

Bashour, H. dan Mamaree, F., 2003. *Gender differences and tuberculosis in the Syrian Arab Republic: patients' attitudes, compliance and outcomes.* EMHJ, **9**: 757–768.

Begum, V., de Colombani, P., Das Gupta, S., Salim Md. A., H., Hussain, H., Pietroni, M., dkk., 2001. *Tuberculosis and patient gender in Bangladesh: sex differences in diagnosis and treatment outcome.* IJTLD, **5**: 604–610.

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Behera, C., Krishna, K., dan Singh, H.R., 2014. Antitubercular drug-induced violent suicide of a hospitalised patient. *Case Reports*, **2014**: bcr2013201469–bcr2013201469.

Bethesda, 2012. *Bedaquiline*, dalam: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD).

Biranu, E., Wolde, M., Negesso, A.E., Hailu Tola, H., dan Molla Sisay, M., 2021. Thyroid Profile and Factors Associated with Hypothyroidism Among Multidrug-Resistant Tuberculosis Patients Attending Saint Peter's Specialized Hospital Addis Ababa, Ethiopia. *Infection and Drug Resistance*, **Volume 14**: 2675–2684.

Bird, S.T., Etminan, M., Brophy, J.M., Hartzema, A.G., dan Delaney, J.A.C., 2013. Risk of acute kidney injury associated with the use of fluoroquinolones. *Canadian Medical Association Journal*, **185**: E475–E482.

Bishop, E., Melvani, S., Howden, B.P., Charles, P.G.P., dan Grayson, M.L., 2006. Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex Patients. *Antimicrobial Agents and Chemotherapy*, **50**: 1599–1602.

Bolhuis, M.S., Tiberi, S., Sotgiu, G., Lorenzo, S.D., Kosterink, J.G.W., Werf, T.S. van der, dkk., 2015. Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study. *European Respiratory Journal*, **46**: 1205–1207.

Borisov, S.E., Dheda, K., Enwerem, M., Romero Leyet, R., D'Ambrosio, L., Centis, R., dkk., 2017. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. *European Respiratory Journal*, **49**: 1700387.

Boyles, T.H., Hughes, J., Cox, V., Burton, R., Meintjes, G., dan Mendelson, M., 2014. False-positive Xpert® MTB/RIF assays in previously treated patients: need for caution in interpreting results. *The International Journal of Tuberculosis and Lung Disease*, **18**: 876–878.

BPOM RI, 2015. 'Cek Produk BPOM - BPOM RI', . URL: https://cekbpom.pom.go.id//home/produk/43697j6btnj7i7m6p0e1lmdrt0/all/row/10/page/1/order/4/DESC/search/5/bedaquiline (diakses tanggal 19/9/2021).

BPOM RI, 2020. *Modul Farmakovigilans Bagi Tenaga Profesional Kesehatan*.

Brewer, L. dan Williams, D., 2012. *Drug Interactions that Matter*. Medicine, Clinical Pharmacology **40**: 371–375.

Buziashvili, M., Mirtskhulava, V., Kipiani, M., Blumberg, H.M., Baliashvili, D., Magee, M.J., dkk., 2019. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia. *The International Journal of Tuberculosis and Lung Disease*, **23**: 1005–1011.

Cameron, L.H. dan Starke, J.R., 2020. *Tuberculosis (Mycobacterium tuberculosis)*, dalam: Nelson Textbook of Pediatrics. Elsevier, hal. 1565–1582.

UNIVERSITAS GADJAH MADA
Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Centers for Disease Control and Prevention, 2013. *Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis.* MMWR, **62**: 8.

Chem, E.D., Van Hout, M.C., dan Hope, V., 2019. *Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub Saharan Africa: a systematic review and meta-analysis.* BMC Infectious Diseases, **19**: 723.

Chiang, S.S. dan Starke, J.R., 2018. *Mycobacterium tuberculosis*, dalam: Principles and Practice of Pediatric Infectious Diseases. Elsevier, hal. 790–806.

Cholo, M.C., Steel, H.C., Fourie, P.B., Germishuizen, W.A., dan Anderson, R., 2012. Clofazimine: current status and future prospects. *Journal of Antimicrobial Chemotherapy*, **67**: 290–298.

Chumakova, E., Abdullaev, R., dan Komissarova, O., 2020a. Hyperuricemia in patients with newly detected MDR tuberculosis. *European Respiratory Journal*, **56**: .

Chumakova, E., Abdullaev, R., dan Komissarova, O., 2020b. Hyperuricemia in patients with newly detected MDR tuberculosis. *European Respiratory Journal*, **56**: .

Court, R., Centner, C.M., Chirehwa, M., Wiesner, L., Denti, P., de Vries, N., dkk., 2021a. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **105**: 688–694.

Court, R., Centner, C.M., Chirehwa, M., Wiesner, L., Denti, P., de Vries, N., dkk., 2021b. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **105**: 688–694.

Cox, E. dan Laessig, K., 2014. *FDA Approval of Bedaquiline — The Benefit–Risk Balance for Drug-Resistant Tuberculosis*. NEJM**, 371**: 689–691.

Cunha, J.P., 2022. 'Side Effects of Paser (Aminosalicylic Acid), Warnings, Uses', *RxList*. URL: https://www.rxlist.com/paser-side-effects-drug-center.htm (diakses tanggal 20/10/2022).

Darmayani, I.G.A.A.P.S., Ascobat, P., Instiaty, Sugiri, Y.J.R., dan Sawitri, N., 2022. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data. *Acta Med Indones-Indones J Intern Med*, **54**: 389–396.

Di Gennaro, F., Vittozzi, P., Gualano, G., Musso, M., Mosti, S., Mencarini, P., dkk., 2020. *Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital.* Antibiotics, **9**: 489.

Diallo, A., Diallo, B.D., Camara, L.M., Kounoudji, L.A.N., Bah, B., N'Zabintawali, F., dkk., 2020. Different profiles of body mass index variation among patients with multidrug-resistant tuberculosis: a retrospective cohort study. *BMC Infectious Diseases*, **20**: 315.

Dinkes Provinsi Jawa Tengah, 2020. *Buku Saku Kesehatan Tahun 2019*. Dinkes Provinsi Jawa Tengah, Semarang.

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020a. *Petunjuk Teknis Pendampingan Pasien Tuberkulosis Resistan Obat Oleh Komunitas*. Kementerian Kesehatan RI, Jakarta.

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2020b. *Petunjuk Teknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*. Kementerian Kesehatan RI, Jakarta.

Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, 2021. *Surat Edaran Kementerian Kesehatan RI Tentang Perubahan Alur Diagnosis Dan Pengobatan Tuberkulosis Di Indonesia*. Kementerian Kesehatan RI.

Dooley, K.E., Rosenkranz, S.L., Conradie, F., Moran, L., Hafner, R., von Groote-Bidlingmaier, F., dkk., 2021. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. *The Lancet Infectious Diseases*, **21**: 975–983.

drugs.com, 2022a. 'Drug Interaction Report: bedaquiline, clofazimine', *Drugs.com*. URL: https://www.drugs.com/interactions-check.php?drug_list=3439-0,699-0 (diakses tanggal 10/9/2022).

drugs.com, 2022b. 'Drug Interaction Report: bedaquiline, ethambutol, pyrazinamide, isoniazid, ethionamide, Paser', *Drugs.com*. URL: https://www.drugs.com/interactions-check.php?drug_list=1033-0,1048-0,1393-0,166-70,1970-0,3439-0 (diakses tanggal 10/9/2022).

Elmi, O.S., Hasan, H., Abdullah, S., Mat Jeab, M.Z., Ba, Z., dan Naing, N.N., 2016. *Treatment Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB) Compared with Non-MDR-TB Infections in Peninsular Malaysia.* MJMS, **23**: 17–25.

Farley, J.E., Ram, M., Pan, W., Waldman, S., Cassell, G.H., Chaisson, R.E., dkk., 2011. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. *PloS One*, **6**: e20436.

Fisher-Hoch, S., Whitney, E., Mccormick, J., Crespo, G., Smith, B., Rahbar, M., dkk., 2009. Type 2 diabetes and multidrug-resistant tuberculosis. *Scandinavian Journal of Infectious Diseases*, **40**: 888–893.

Fitzgerald, D.W., Sterling, T.R., dan Haas, D.W., 2020. *Mycobacterium tuberculosis,* dalam: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier Inc, hal. 2985–3021.

Fox, G.J. dan Menzies, D., 2013. *A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis.* Infectious Diseases and Therapy, **2**: 123–144.

Gadallah, M.A., Mokhtar, A., Rady, M., El-Moghazy, E., Fawzy, M., dan Kandil, S.K., 2016. *Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt*. JFMA, **115**: 997–1003.

Ganiger, A., Patil, L., dan Mrudula, N., 2019. Evaluation of Serum Electrolyte Status among Normal Healthy Individuals and Newly Diagnosed Cases of Pulmonary TB in Tertiary Care Hospital in Bidar: An Observational Study. *Indian Journal of Medical Biochemistry*, **23**: 316–319.

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Gao, J.-T., 2021. *Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety 10*.

Ghori, S.S., Quddus, M.A., dan Khalid, H., 2017. A Clinical Study of Acute Kidney Injury on using Antituberculosis Drugs in Geriatrics. *Research Journal of Pharmacy and Technology*, **10**: 1746–1750.

Guglielmetti, L., Tiberi, S., Burman, M., Kunst, H., Wejse, C., Togonidze, T., dkk., 2018. QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) study. *European Respiratory Journal*, **52**: 1800537.

Habibi, M.R., Bakhtiar, A., Indiastuti, D.N., dan Meliana, R.Y., 2022. Diabetes Mellitus and History of Tuberculosis Treatment as Risk Factors of Developing Multidrug-Resistant Tuberculosis at TB Polyclinic Dr. Soetomo General Hospital 2019 - 2020. *Jurnal Ilmiah Universitas Batanghari Jambi*, **22**: 537.

Hartshorn, E.A. dan Tatro, D.S., 2015. *Principles of Drug Interactions*, dalam: Drug Interaction Facts 2015: The Authority on Drug Interactions. Wolters Kluwer Health, St. Louis, Missouri, hal. xvii.

Hewison, C., Khan, U., Bastard, M., Lachenal, N., Coutisson, S., Osso, E., dkk., 2022. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. *Clinical Infectious Diseases*, **75**: 1006–1013.

Heysell, S.K., Ahmed, S., Rahman, Md.T., Akhanda, Md.W., Gleason, A.T., Ebers, A., dkk., 2018a. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. *European Respiratory Journal*, **51**: 1701778.

Heysell, S.K., Ahmed, S., Rahman, Md.T., Akhanda, Md.W., Gleason, A.T., Ebers, A., dkk., 2018b. Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. *European Respiratory Journal*, **51**: 1701778.

Ibrahim, L.M., Hadejia, I.S., Nguku, P., Dankoli, R., Waziri, N.E., Akhimien, M.O., dkk., 2014. Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State, Nigeria. 2011. *The Pan African Medical Journal*, **17**: 78.

Ignatius, E.H. dan Dooley, K.E., 2019. *New Drugs for the Treatment of Tuberculosis.* Clinics in Chest Medicine, **40**: 811–827.

Isaakidis, P., Casas, E.C., Das, M., Tseretopoulou, X., Ntzani, E.E., dan Ford, N., 2015. *Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis.* IJTLD, **19**: 969–978.

Isralls, S., Baisley, K., Ngam, E., Grant, A.D., dan Millard, J., 2021. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study. *Open Forum Infectious Diseases*, **8**: ofab413.

Ja, J., 2000. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. *International journal of clinical pharmacology and therapeutics*, **38**: .

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Jamaluddin, Nizamuddin, Shah, A., dan Iqbal, W., 2018. Hyperuricemia in Patients Taking Anti-Tuberculosis Drugs Including Pyrazinamide for both Category-1 and Category-2 Tuberculosis, in Population of KPK-Pakistan. *Med. Forum*, **29**: 5.

Jan, F., Hasan, M., Muhamad, N., Wali, S., Akbar, H.S., Atta, Q.M., dkk., 2017. Electrolytes imbalance caused by amikacin in patients receiving multi drug resistance- tuberculosis treatment at Hazara region Kpk, Pakistan. *Tuberkuloz ve Toraks*, **65**: 193–201.

John, F., Oluronbi, R., dan Pitchumoni, C.S., 2016. Levofloxacin-induced rhabdomyolysis: a case report. *Journal of Medical Case Reports*, **10**: 235.

Kandasamy, A. dan Srinath, D., 2012. Levofloxacin-induced acute anxiety and insomnia. *Journal of Neurosciences in Rural Practice*, **3**: 212–214.

Kardalas, E., Paschou, S.A., Anagnostis, P., Muscogiuri, G., Siasos, G., dan Vryonidou, A., 2018. Hypokalemia: a clinical update. *Endocrine Connections*, **7**: R135–R146.

Karim, F., Ahmed, F., Begum, I., Johansson, E., dan Diwan, V.K., 2008. *Female-male differences at various clinical steps of tuberculosis management in rural Bangladesh [Short communication]*. IJTLD, **12**: 1336–1339.

Katrak, S., Lowenthal, P., Shen, R., True, L., Henry, L., dan Barry, P., 2021. Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **23**: 100216.

Kazi, S. dan Preston, G., 2018. Drug Induced Thrombotic Microangiopathy Caused by Levofloxacin. *Journal of the Royal College of Physicians of Edinburgh*, **48**: 127–129.

Kementerian Kesehatan RI, 2016. *Peraturan Menteri Kesehatan Republik Indonesia No. 67 Tahun 2016 Tentang Penanggulangan Tuberkulosis*. Kemenkes RI, Jakarta.

Kementerian Kesehatan RI, 2020. *Juknis Penatalaksanaan Tuberkulosis Resistan Obat di Indonesia*. Kemenkes RI, Jakarta.

Kempker, R.R., Barth, A.B., Vashakidze, S., Nikolaishvili, K., Sabulua, I., Tukvadze, N., dkk., 2015. *Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis.* Antimicrobial Agents and Chemotherapy

Kervezee, L., Gotta, V., Stevens, J., Birkhoff, W., Kamerling, I., Danhof, M., dkk., 2016. Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration. *CPT: Pharmacometrics & Systems Pharmacology*, **5**: 466–474.

Khan, F.A., Salim, M.A.H., Cros, P. du, Casas, E.C., Khamraev, A., Sikhondze, W., dkk., 2017. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. *European Respiratory Journal*, **50**: .

Khan, S., Andries, A., Pherwani, A., Saranchuk, P., dan Isaakidis, P., 2014. Patch-testing for the management of hypersensitivity reactions to second-line anti-tuberculosis drugs: a case report. *BMC Research Notes*, **7**: 537.

UNIVERSITAS
GADJAH MADA
**Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang**
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Kim, J., Kwak, N., Lee, H.Y., Kim, T.S., Kim, C.-K., Han, S.K., dkk., 2016. *Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis.* IJID**, 42**: 64–68.

Kondoy, P.P.H., Rombot, D.V., Palandeng, H.M.F., dan Pakasi, T.A., 2014. Faktor-Faktor Yang Berhubungan Dengan Kepatuhan Berobat Pasien Tuberkulosis Paru di Lima Puskesmas di Kota Manado. *JURNAL KEDOKTERAN KOMUNITAS DAN TROPIK*, **2**: .

Kuchukhidze, G., Kumar, A.M.V., de Colombani, P., Khogali, M., Nanava, U., Blumberg, H.M., dkk., 2014. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. *Public Health Action*, **4**: S41–S46.

Kumar, R., Khan, S., Sen, P., dan Banerjee, S., 2020. A Study to Detect Liver Enzyme Dysfunction among Patients on First Line Anti-Tubercular Drugs from RNTCP during the Course of Anti-TB Treatment. *Journal of Evolution of Medical and Dental Sciences*, **9**: 645–650.

Kurniawati, F., Sulaiman, S.A.S., dan Gillani, S.W., 2012. Study On Drug-Resistant Tuberculosis And Tuberculosis Treatment On Patients With Drug Resistant Tuberculosis In Chest Clinic Outpatient Department **4**: 5.

Lan, Zhiyi, Ahmad, Nafees, Baghaei, Parvaneh, Barkane, Linda, Benedetti, Andrea, Brode, S.K., dkk., 2020. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *The Lancet Respiratory Medicine*, **8**: 383–394.

Lange, C., Abubakar, I., Alffenaar, J.-W.C., Bothamley, G., Caminero, J.A., Carvalho, A.C.C., dkk., 2014. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. *European Respiratory Journal*, **44**: 23–63.

Lawrence Flick Memorial Tuberculosis Clinic, 1998. *Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents*. Philadelphia Tuberculosis Control Program.

Li, J., Yang, G., Cai, Q., Wang, Y., Xu, Y., Zhang, R., dkk., 2021. Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **110**: 179–186.

Li, M. dan Ramos, L.G., 2017. Drug-Induced QT Prolongation And Torsades de Pointes. *Pharmacy and Therapeutics*, **42**: 473–477.

Li, Y., Wang, F., Wu, L., Zhu, M., He, G., Chen, X., dkk., 2019. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. *Infection and Drug Resistance*, **Volume 12**: 721–731.

Liu, Q., Lu, P., Martinez, L., Yang, H., Lu, W., Ding, X., dkk., 2018. *Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China.* BMC Infectious Diseases, **18**: 114.

Lofranco, V.S., Jr, V.M.B., Raymond, L.O., Macalalad, N.G., Golubkov, A., Santiago, M.R.T., dkk., 2022a. Effectiveness and Safety of 9-Month Treatment Regimen for Multidrug-Resistant Tuberculosis in the Philippines. *Journal of Tuberculosis Research*, **10**: 75–86.

UNIVERSITAS GADJAH MADA
Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Lofranco, V.S., Torres-Cervas, M.R.A., Asence, K.A., Del Mundo, K.M.A., Balanag, V.M., Santiago, M.R.T., dkk., 2022b. Interim Outcomes and Adverse Events among Drug-Resistant Tuberculosis Patients Treated with Bedaquiline in the Philippines. *Journal of Tuberculosis Research*, **10**: 61–74.

Lv, L., Li, T., Xu, K., Shi, P., He, B., Kong, W., dkk., 2018. *Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis.* Infection and Drug Resistance, **11**: 147–154.

Mafukidze, A.T., Calnan, M., dan Furin, J., 2016a. Peripheral neuropathy in persons with tuberculosis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2**: 5–11.

Mafukidze, A.T., Calnan, M., dan Furin, J., 2016b. Peripheral neuropathy in persons with tuberculosis. *Journal of Clinical Tuberculosis and Other Mycobacterial Diseases*, **2**: 5–11.

Management Sciences for Health and World Health Organization, 2007. *Drug and Therapeutics Committee Training Course*. Management Sciences for Health, Geneva.

Mantefardo, B. dan Sisay, G., 2021a. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. *International Medical Case Reports Journal*, **Volume 14**: 815–817.

Mantefardo, B. dan Sisay, G., 2021b. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. *International Medical Case Reports Journal*, **14**: 3.

Mase, S., Chorba, T., Parks, S., Belanger, A., Dworkin, F., Seaworth, B., dkk., 2020a. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, **71**: 1010–1016.

Mase, S., Chorba, T., Parks, S., Belanger, A., Dworkin, F., Seaworth, B., dkk., 2020b. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. *Clinical Infectious Diseases*, **71**: 1010–1016.

Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., dkk., 2019. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. *Emerging Infectious Diseases*, **25**: 11.

McGee, E.U., Samuel, E., Boronea, B., Dillard, N., Milby, M.N., dan Lewis, S.J., 2019. Quinolone Allergy. *Pharmacy: Journal of Pharmacy Education and Practice*, **7**: 97.

Menon, S., Dharmshale, S., Chande, C., Gohil, A., Lilani, S., Mohammad, S., dkk., 2012. Drug resistance profiles of Mycobacterium tuberculosis isolates to first line anti-tuberculous drugs: A five years study. *Lung India : Official Organ of Indian Chest Society*, **29**: 227–231.

Minardi, M.L., Fato, I., Di Gennaro, F., Mosti, S., Mastrobattista, A., Cerva, C., dkk., 2021. Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. *Microorganisms*, **9**: 1477.

Molla, Y., Wubetu, M., dan Dessie, B., 2021. Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Selected Hospitals, Ethiopia. *Hepatic Medicine: Evidence and Research*, **13**: 1–8.

Muhammad, N., Mehboob, S., dan Abbas, M., 2021. Pyrazinamide Induced Hyperuricemia in the Induction Phase of Anti-Tuberculosis Therapy. *Pakistan Journal of Medical and Health Sciences*, **15**: 1136–1138.

Munivenkatappa, S., Anil, S., Naik, B., Volkmann, T., Sagili, K.D., Akshatha, J.S., dkk., 2016. Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field. *Journal of Tuberculosis Research*, **04**: 105–110.

Nasiri, M.J., Imani Fooladi, A.A., Dabiri, H., Pormohammad, A., Salimi Chirani, A., Dadashi, M., dkk., 2016. Primary ethambutol resistance among Iranian pulmonary tuberculosis patients: a systematic review. *Therapeutic Advances in Infectious Disease*, **3**: 133–138.

Nugroho, N.P. dan Kusmiati, T., 2021. Allergic Reaction due to Anti-Tuberculosis Drugs, How to Manage? *Jurnal Respirasi*, **7**: 79.

Oehadian, A., Santoso, P., Menzies, D., dan Ruslami, R., 2022. Anemia with elevation of growth differentiation factor-15 level in linezolid treated multidrug-resistant tuberculosis: Case series of three patients. *IDCases*, **29**: e01591.

Oh, Y.R., Carr-Lopez, S.M., Probasco, J.M., dan Crawley, P.G., 2003. Levofloxacin-induced autoimmune hemolytic anemia. *The Annals of Pharmacotherapy*, **37**: 1010–1013.

Palomino, J.C. dan Martin, A., 2013. TMC207 becomes bedaquiline, a new anti-TB drug. *Future Microbiology*, **8**: 1071–1080.

Parmar, M.M., Sachdeva, K.S., Dewan, P.K., Rade, K., Nair, S.A., Pant, R., dkk., 2018. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement. *PLOS ONE*, **13**: e0193903.

Pham, Antony Q., Doan, A., dan Andersen, M., 2014. Pyrazinamide-Induced Hyperuricemia. *Pharmacy and Therapeutics*, **39**: 695–715.

Pham, Antony Q, Doan, A., dan Andersen, M., 2014. Pyrazinamide-Induced Hyperuricemia. *Pharmacovigilance Forum*, **39**: 4.

Pichholiya, M., Yadav, A.K., Luhadia, S.K., Tahashildar, J., dan Aseri, M.L., 2016. A comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients. *Indian Journal of Pharmacology*, **48**: 522–525.

Pizzol, D., Veronese, N., Marotta, C., Di Gennaro, F., Moiane, J., Chhaganlal, K., dkk., 2018. Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. *BMC Research Notes*, **11**: .

Polprasert, C. dan Prayongratana, K., 2009. Levofloxacin-induced severe thrombocytopenia. *Journal of the Medical Association of Thailand = Chotmaihet Thangphaet*, **92 Suppl 3**: S69-71.

Pradipta, I., 2020. 'Improving treatment outcomes of tuberculosis: towards an antimicrobial stewardship program', . University of Groningen.

UNIVERSITAS GADJAH MADA
Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Pratama, N.Y.I., Zulkarnain, B.S., Soedarsono, null, dan Fatmawati, U., 2021a. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 777–781.

Pratama, N.Y.I., Zulkarnain, B.S., Soedarsono, dan Fatmawati, U., 2021b. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy. *Journal of Basic and Clinical Physiology and Pharmacology*, **32**: 777–781.

Primadana, V., Yovi, I., dan Estiningsih, D.S., 2022. Bedaquiline Correlation to QT Interval Prolongation in DR-TB Patients. *Jurnal Respirasi*, **08**: 7.

Putra, I.W.A., Lonovi, K., Damayanti, L., dan Kamajaya, T., 2021. 'Characteristic of SGOT and SGPT Elevation in Patient with Lung Tuberculosis within OAT Therapy:: From Lung Policlinic RSUP Dr. Hasan Sadikin Bandung within 2016', . Dipresentasikan pada 12th Annual Scientific Meeting, Medical Faculty, Universitas Jenderal Achmad Yani, International Symposium on "Emergency Preparedness and Disaster Response during COVID 19 Pandemic" (ASMC 2021)), Bandung, Indonesia.

Putra, O.N., N.h, A.Y., Hidayat, F., dan Sagitha, I.G.E., 2022. Ototoxicity in Multidrug-Resistant Tuberculosis: A Scoping Review of the Indonesian Studies. *Journal of Pharmaceutical And Sciences*, **5**: 62–73.

Rahman, A.O. dan Thobari, J.A., 2012. Association of hydrazine and SGPT level two hours after drug administration at the end of intensive phase treatment of pulmonary tuberculosis patients. *Tropical Medicine Journal*, **02**: 10.

Ramappa, V. dan Aithal, G.P., 2013. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *Journal of Clinical and Experimental Hepatology*, **3**: 37–49.

Reis-Santos, B., Gomes, T., Horta, B.L., dan Maciel, E.L.N., 2013. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinomial analysis. *Jornal Brasileiro de Pneumologia*, **39**: 585–594.

Rich, M.L., Seung, K.J., Tavares, A.C., Barrera-Cancedda, A.E., dan Tierney, D., 2013. *The PIH Guide to the Medical Management of Multidrug-Resistant Tuberculosis*, 2nd ed. Partners In Health, Boston, USA.

Rifat, M., Hall, J., Oldmeadow, C., Husain, A., Hinderaker, S.G., dan Milton, A.H., 2015. Factors related to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis in Bangladesh. *BMJ Open*, **5**: e008273.

Rumende, C.M., 2018. Diagnosis dan Tatalaksana Tuberkulosis Resistan Obat 9.

Sandhu, P. dan Akhter, Y., 2018. Evolution of structural fitness and multifunctional aspects of mycobacterial RND family transporters. *Archives of Microbiology*, **200**: 19–31.

Saraf, G., Akshata, J.S., Kuruthukulangara, S., Thippeswamy, H., Reddy, S.K., Buggi, S., dkk., 2015. Cycloserine induced delirium during treatment of multi-drug resistant tuberculosis (MDR-TB). *Egyptian Journal of Chest Diseases and Tuberculosis*, **64**: 449–451.

Sari, T.N., Retnowulan, H., Hisyam, B., Riyanto, B.S., Budiono, E., dan Trisnawati, I., 2016. Interaction of Side Effects of Second Line TB Drugs

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Therapy in MDR-TB: Ethionamide- induced Hypothyroid and Cycloserine-induced Depression Episode. *Indonesian Journal of Critical and Emergency Medicine*, **3**: 5.

Sasongko, D. dan Hasan, H., 2020. Factors Affecting Uric Acid Changes in Pulmonary Tuberculosis Patients Who Received Oral Anti Tuberculosis Therapy During One Month. *Medico-Legal Update*, **20**: 836–842.

Satti, H., Mafukidze, A., Jooste, P.L., McLaughlin, M.M., Farmer, P.E., dan Seung, K.J., 2012. High rate of hypothyroidism among patients treated for multidrug-resistant tuberculosis in Lesotho. *The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease*, **16**: 468–472.

Saxena, R., Singh, D., Phuljhele, S., Kalaiselvan, V., Karna, S., Gandhi, R., dkk., 2021. Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy. *Indian Journal of Ophthalmology*, **69**: 3734–3739.

Sayamber, A., 2017. A study of changes in SGPT and SGOT over time the patients of drug induced hepatitis taking antitubercular drugs **3**: 7.

Scardigli, A., Caminero, J.A., Sotgiu, G., Centis, R., D'Ambrosio, L., dan Migliori, G.B., 2016. Efficacy and tolerability of ethionamide versus prothionamide: a systematic review. *European Respiratory Journal*, **48**: 946–952.

Schnippel, K., Ndjeka, N., Maartens, G., Meintjes, G., Master, I., Ismail, N., dkk., 2018. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. *The Lancet Respiratory Medicine*, **6**: 699–706.

Seaworth, B. dan Griffith, D.E., 2016. Adverse reactions and toxicity should be anticipated with any treatment course for drug-resistant TB., dalam: *Drug-Resistant Tuberculosis: A Survival Guide for Clinicians*. Curry International Tuberculosis Center, San Francisco, hal. 32.

Seung, K.J., Keshavjee, S., dan Rich, M.L., 2015. Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. *Cold Spring Harbor Perspectives in Medicine*, **5**: a017863.

Shang, P., Xia, Y., Liu, F., Wang, X., Yuan, Y., Hu, D., dkk., 2011. Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China. *PLOS ONE*, **6**: e21836.

Sharma, B., Handa, R., Nagpal, K., Prakash, S., Gupta, P.K., dan Agrawal, R., 2014. Cycloserine-induced psychosis in a young female with drug-resistant tuberculosis. *General Hospital Psychiatry*, **36**: 451.e3–4.

Sharma, S., 2014. *Nursing Research & Statistics*, Second Edition. ed. Elsevier Health Sciences APAC, London.

Sheikh-Taha, M. dan Frenn, P., 2014. Autoimmune Hemolytic Anemia Induced by Levofloxacin. *Case Reports in Infectious Diseases*, **2014**: 201015.

Shibeshi, W., Sheth, A.N., Admasu, A., Berha, A.B., Negash, Z., dan Yimer, G., 2019. Nephrotoxicity and ototoxic symptoms of injectable second-line

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study. *BMC Pharmacology and Toxicology*, **20**: 31.

Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., dkk., 2004a. Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. *CHEST*, **125**: 974–980.

Shin, S., Furin, J., Alcántara, F., Hyson, A., Joseph, K., Sánchez, E., dkk., 2004b. Hypokalemia Among Patients Receiving Treatment for Multidrug-Resistant Tuberculosis. *Chest*, **125**: 974–980.

Shinnick, T.M., Starks, A.M., Alexander, H.L., dan Castro, K.G., 2015. Evaluation of the Cepheid Xpert MTB/RIF assay. *Expert review of molecular diagnostics*, **15**: 9–22.

Soedarsono, S. dan Riadi, A.R.W., 2020. Tuberculosis Drug-Induced Liver Injury. *Jurnal Respirasi*, **6**: 49.

Soeroto, A.Y., Darmawan, G., Supriyadi, R., Bhaskara, P.G., Santoso, P., Alisjahbana, B., dkk., 2019. Comparison of Serum Potassium, MagnEsium, and Calcium Levels between Kanamycin and Capreomycin-BASEd Regimen-Treated MultiDrug-Resistant TuBerculosis Patients in Bandung (CEASE MDR-TB): A Retrospective Cohort Study. *International Journal of Microbiology*, **2019**: 1–7.

Soeroto, A.Y., Pratiwi, C., Santoso, P., dan Lestari, B.W., 2021. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: A retrospective cohort study. *PLOS ONE*, **16**: e0246284.

Stettner, M., Steinberger, D., Hartmann, C.J., Pabst, T., Konta, L., Hartung, H.P., dkk., 2015. Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? *Brain and Behavior*, **5**: n/a-n/a.

Sultana, Z.Z., Hoque, F.U., Beyene, J., Akhlak-Ul-Islam, Md., Khan, M.H.R., Ahmed, S., dkk., 2021. HIV infection and multidrug resistant tuberculosis: a systematic review and meta-analysis. *BMC Infectious Diseases*, **21**: 51.

Suparyatmo, J.B., Rina, B., Harsini, dan Sukma, 2014. Kalium di Multidrug Resistance Tuberkulosis dengan Pengobatan Kanamisin. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, **21**: 16–19.

Teng, C., Walter, E.A., Gaspar, D.K.S., Obodozie-Ofoegbu, O.O., dan Frei, C.R., 2019. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. *International Journal of Medical Sciences*, **16**: 1018–1022.

Theron, G., Venter, R., Smith, L., Esmail, A., Randall, P., Sood, V., dkk., 2018. False-Positive Xpert MTB/RIF Results in Retested Patients with Previous Tuberculosis: Frequency, Profile, and Prospective Clinical Outcomes. *Journal of Clinical Microbiology*, **56**: e01696-17.

Thumamo Pokam, B., Enoh, J., Eyo, A.-A., Umoh, N., dan Guemdjom, P., 2018. Uric acid levels in patients on antituberculosis drugs in the southwest Region of Cameroon. *International Journal of Mycobacteriology*, **7**: 89.

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Tiwari, M., Patel, M., dan Shamaliya, K., 2015. Peripheral neuropathy in XDR-TB patients on second line anti-tubercular therapy. *European Respiratory Journal*, **46**: .

Tola, H.H., Holakouie-Naieni, K., Lejisa, T., Mansournia, M.A., Yaseri, M., Tesfaye, E., dkk., 2019. Is hypothyroidism rare in multidrug resistance tuberculosis patients on treatment? A systematic review and meta-analysis. *PLOS ONE*, **14**: e0218487.

Tornheim, J.A., Udwadia, Z.F., Arora, P.R., Gajjar, I., Gupte, N., Sharma, S., dkk., 2022. Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis. *European Respiratory Journal*, **59**: 2102511.

Tupasi, T.E., Garfin, A.M.C.G., Kurbatova, E.V., Mangan, J.M., Orillaza-Chi, R., Naval, L.C., dkk., 2016. Factors Associated with Loss to Follow-up during Treatment for Multidrug-Resistant Tuberculosis, the Philippines, 2012–2014. *Emerging Infectious Diseases*, **22**: 491–502.

Vishnu, V.Y., Modi, M., Goyal, M.K., dan Lal, V., 2016. Linezolid Induced Reversible Peripheral Neuropathy. *American Journal of Therapeutics*, **23**: e1839–e1841.

Wallis, R.S., 2016. Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. *European Respiratory Journal*, **48**: 1526–1527.

Wang, C.S., Yang, C.J., Chen, H.C., Chuang, S.H., Chong, I.W., Hwang, J.J., dkk., 2009. Impact of type 2 diabetes on manifestations and treatment outcome of pulmonary tuberculosis. *Epidemiology and Infection*, **137**: 203–210.

Wen, Y., Zhang, Z., Li, X., Xia, D., Ma, J., Dong, Y., dkk., 2018. Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study. *BMC Infectious Diseases*, **18**: 104.

WHO, 2009. *Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI).*, Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI). World Health Organization.

WHO, 2013. 'The Use of the WHO-UMC System For Standardised Case Causality Assessment', .

WHO, W.H.O., 2010. *Treatment of Tuberculosis: Guidelines*, 4th ed. World Health Organization, Geneva, Switzerland.

WHO, [World Health Organization], 2015. *Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level*. WHO press, Geneva, Switzerland.

Widyasrini, E.R., Masters Program in Family Medicine, Sebelas Maret University, Probandari, A.N., Faculty of Medicine, Sebelas Maret University, -, R., dan Department of Pulmonology and Respiratory

Efektivitas dan Keamanan Regimen Berisi Bedaquiline pada Pasien TB Resisten Obat di RSUP Dr. Kariadi
Semarang
NIKEN PUSPITASARI, Dr. apt. Ika Puspitasari, M.Si ; Prof. dr. Titik Nuryastuti, M.Si., Ph.D, SpMK(K)
Universitas Gadjah Mada, 2022 | Diunduh dari http://etd.repository.ugm.ac.id/

Medicine, Dr. Moewardi, Surakarta, 2017. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. *Journal of Epidemiology and Public Health*, **02**: 45–57.

World Health Organization, 2013. *The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis: Interim Policy Guidance.* World Health Organization, Geneva.

World Health Organization, 2014. *Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis*. World Health Organization, Geneva.

World Health Organization, 2015. *Introduction of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis at Country Level*. World Health Organization, Geneva.

World Health Organization, 2020a. 'Global Tuberculosis Report 2020', . World Health Organization, Geneva.

World Health Organization, 2020b. 'Tuberculosis (TB)', . URL: https://www.who.int/news-room/fact-sheets/detail/tuberculosis (diakses tanggal 18/9/2021).

World Health Organization, 2020c. *WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment*. WHO, Geneva.

Wulandari, I.S.M., Rantung, J., dan Malinti, E., 2020. Faktor yang Berhubungan dengan Kepatuhan Minum Obat Pasien TBC di Wilayah Kerja Puskesmas Parongpong. *Jurnal Keperawatan Muhammadiyah*, **5**: .

Yang, T.W., Park, H.O., Jang, H.N., Yang, J.H., Kim, S.H., Moon, S.H., dkk., 2017a. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. *Medicine*, **96**: e7482.

Yang, T.W., Park, H.O., Jang, H.N., Yang, J.H., Kim, S.H., Moon, S.H., dkk., 2017b. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. *Medicine*, **96**: e7482.

Yu, M.-C., Chiang, C.-Y., Lee, J.-J., Chien, S.-T., Lin, C.-J., Lee, S.-W., dkk., 2018. Treatment Outcomes of Multidrug-Resistant Tuberculosis in Taiwan: Tackling Loss to Follow-up. *Clinical Infectious Diseases*, **67**: 202–210.

Zhurkin, D., Gupta, R.K., Gadoev, J., Dadu, A., Davtyan, K., Hurevich, H., dkk., 2019. Effectiveness and safety of bedaquiline-containing regimens among adults with multidrug- or extensively drug-resistant pulmonary TB in Belarus: a nationwide cohort study **5**: 9.